Concepedia

James K. Hogan

JK

Statistics

Publications

11

Citations

667

H-Index

11

Active since

1992

Affiliations

Vertex Pharmaceuticals (United States)(Current)

James K. Hogan is an author at Vertex Pharmaceuticals (United States) specializing in medicine, biochemistry, and natural sciences.

Top concepts

Publications per year

1992–2015

11

Publications

11

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.

David H.‐F. Teng, William L. Perry, James K. Hogan et al. · PubMed · 1997 · 193 citations

, , +19

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

, , +16

The Marine Cyanobacterial Metabolite Gallinamide A Is a Potent and Selective Inhibitor of Human Cathepsin L

Bailey W. Miller, Aaron J. Friedman, Hyukjae Choi et al. · Journal of Natural Products · 2013 · 76 citations · Full text

, , +20

Investigation of protein refolding using a fractional factorial screen: A study of reagent effects and interactions

Melissa Swope Willis, James K. Hogan, Prakash Prabhakar et al. · Protein Science · 2005 · 74 citations · Full text

, , +19

VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease

Sudipta Mahajan, James K. Hogan, Dina Shlyakhter et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 60 citations

1–5 of 11